This clinical trial is focused on studying the effects of a medication called nalmefene on individuals with certain types of behavioral addictions. These addictions include gambling disorder, sexual addiction, and food addiction. The study aims to see if nalmefene can help reduce the intensity of cravings that people with these addictions experience. Participants in the study will receive either nalmefene or a placebo, which is a substance that looks like the medication but does not have any active ingredients.
The purpose of the study is to assess how effective nalmefene is when used alongside the usual treatment for these addictions. Participants will be asked to regularly report their craving episodes over the course of the study. The study will track changes in the intensity, frequency, and duration of these cravings from the start to the end of the treatment period. Additionally, the study will look at overall clinical improvement and any side effects experienced by participants.
The study will last for a period of time, during which participants will take the medication or placebo and report their experiences. The goal is to gather information on how nalmefene affects cravings and whether it can be a helpful addition to existing treatments for behavioral addictions. This information will help researchers understand the potential benefits and any risks associated with using nalmefene for these conditions.



France